<DOC>
	<DOC>NCT02195869</DOC>
	<brief_summary>The purpose of this study is to assess the safety and clinical efficacy of ibrutinib in subjects with steroid dependent or refractory Chronic Graft Versus Host Disease.</brief_summary>
	<brief_title>Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease</brief_title>
	<detailed_description />
	<mesh_term>Graft vs Host Disease</mesh_term>
	<criteria>Steroid dependent or refractory classic chronic GVHD disease. No more than 3 previous treatments for cGVHD. Receiving baseline systemic glucocorticoid therapy (at stable dose) for cGVHD at study entry. Men and women ≥18 years old. Karnofsky performance status ≥60. Known or suspected active acute GVHD. Current treatment with sirolimus AND either cyclosporine or tacrolimus. History of treatment with a tyrosine kinase inhibitor (eg, imatinib), purine analogs or other cancer chemotherapy in the 4 weeks prior to starting study drug. Currently active, clinically significant cardiovascular disease. Uncontrolled infections not responsive to antibiotics, antiviral medicines, or antifungal medicines or a recent infection requiring systemic treatment that was completed ≤14 days before the first dose of study drug. Progressive underlying malignant disease including posttransplant lymphoproliferative disease. History of other malignancy (not including the underlying malignancy that was the indication for transplant) Concomitant use of warfarin or other Vitamin K antagonists Known bleeding disorders or hemophilia. History of stroke or intracranial hemorrhage within 6 months prior to enrollment. Known history of human immunodeficiency virus (HIV) or active with hepatitis C virus (HCV) or hepatitis B virus (HBV). Concurrent use of a strong cytochrome P450(CYP) 3A inhibitor.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>PCYC1129</keyword>
	<keyword>PCYC1129CA</keyword>
	<keyword>1129</keyword>
	<keyword>Ibrutinib</keyword>
	<keyword>PCI32765</keyword>
	<keyword>IMBRUVICA</keyword>
	<keyword>Pharmacyclics</keyword>
	<keyword>PCYC</keyword>
	<keyword>GVHD</keyword>
	<keyword>Steroid dependent</keyword>
	<keyword>refractory</keyword>
	<keyword>chronic</keyword>
	<keyword>graft versus host disease</keyword>
	<keyword>chronic graft versus host disease</keyword>
	<keyword>immunology</keyword>
</DOC>